Synapse - Works

Results (4297)

Targeting the cell cycle regulated CDC7 kinase pathway as a novel therapeutic approach for hematologic malignancies

Meeting Abstract

Santos, R.; Shum, D.; Churchill, M.; Mukherjee, S.; Brentjens, R. J.; Jurcic, J. G.; Kelly, T.; Djaballah, H.; Frattini, M. G.
Clinical Lymphoma, Myeloma and Leukemia (2014)

Fulltext@MSK | Save

Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumors

Meeting Abstract

Santos, R.; Shum, D.; Carrillo, D.; Zhang, R.; Churchill, M.; Mukherjee, S.; Brentjens, R.; Radu, C.; Kelly, T. J.; Djaballah, H.; more...
European Journal of Cancer (2014)

Fulltext@MSK | Save

Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (pts) without prior chemotherapy

Meeting Abstract

Ryan, C. J.; Smith, M. R.; Fizazi, K.; Miller, K.; Mulders, P.; Sternberg, C. N.; Saad, F.; Griffin, T.; De Porre, P.; Park, Y. C.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules

Meeting Abstract

Robert, C.; Joshua, A. M.; Weber, J. S.; Ribas, A.; Hodi, F. S.; Kefford, R. F.; Daud, A.; Wolchok, J. D.; Hwu, W. J.; Gangadhar, T. C.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeutics

Meeting Abstract

Reimer, J.; Kovulchuk, A.; Ruan, Y.; Shah, R.; Jayanthan, A.; Perinpanayagam, M.; Truong, T.; Auer-Grzesiak, I.; Luider, J.; Kovulchuk, O.; more...
European Journal of Cancer (2014)

Fulltext@MSK | Save

Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

Meeting Abstract

Pollyea, D. A.; de Botton, S.; Fathi, A. T.; Stein, E. M.; Tallman, M. S.; Agresta, S.; Bowden, C.; Fan, B.; Prah, M.; Yang, H.; more...
European Journal of Cancer (2014)

Fulltext@MSK | Save

Phase 1B trial of anti-notch 2/3 antibody OMP-59R5 in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC): The pinnacle study

Meeting Abstract

Pietanza, M. C.; Spira, A.; Jotte, R.; Gadgeel, S.; Mita, A.; Liu, S.; Gluck, W. L.; Kalemkerian, G. P.; Chiang, A.; Hart, L.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG (alliance) N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC)

Meeting Abstract

Perez, E. A.; Holmes, E.; de Azambuja, E.; Dueck, A.; Baselga, J.; Viale, G.; Zujewski, J. A.; Goldhirsch, A.; Crescenzo, R.; Pritchard, K.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in western countries: A report from The International DLBCL Rituximab-CHOP Consortium Program

Meeting Abstract

Ok, C. Y.; Xu-Monette, Z. Y.; Visco, C.; Tzankov, A.; Montes-Moreno, S.; Dybkaer, K.; Chiu, A.; Orazi, A.; Zu, Y. L.; Bhagat, G.; more...
Clinical Lymphoma, Myeloma and Leukemia (2014)

Fulltext@MSK | Save

Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (MRCC)

Meeting Abstract

Motzer, R. J.; Rini, B. I.; McDermott, D. F.; Redman, B.; Kuzel, T.; Harrison, M. R.; Vaishampayan, U. N.; Drabkin, H.; George, S.; Logan, T.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save